Business Segments Ind-Swift Laboratories Limited Bombay S.E.
Stocks
INDSWFTLAB
INE915B01019
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 187.25 INR | +11.13% |
|
+14.95% | +112.33% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Medicinal Chemicals and Botanical Products | ||||||||||
Pharmaceutical Business | 9.07B | 10.52B | 12.16B | 12.97B | 5.62B | |||||
Total Assets | 18.18B | 18.01B | 18.24B | 11.65B | 14.38B | |||||
Interest Expense | -934M | -915M | -864M | -467M | -13.83M | |||||
Income Tax Expense | 212M | 147M | 387M | 1.6B | 72.7M | |||||
CAPEX | -43.97M | -184M | -128M | -445M | -644M | |||||
EBT | 180M | 125M | 865M | 5.82B | 2.58B | |||||
D&A | 552M | 1.3B | 574M | 533M | 221M | |||||
Net Income | -31.47M | -21.49M | 476M | 4.21B | 2.5B |
Geographical Revenue Distribution History
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Export | 6.72B | 7.96B | 9.37B | 10.02B | 4.06B | |||||
Total Assets | 1.36B | 2.07B | 2.25B | 512M | - | |||||
Operating Income | 2.54B | 2.89B | 3.76B | 4.5B | - | |||||
India | 2.19B | 2.43B | 2.7B | 2.79B | 1.56B | |||||
Total Assets | 3.65B | 2.75B | 3.04B | 1.07B | - | |||||
Operating Income | 806M | 856M | 813M | 1.05B | - | |||||
Unallocated | 227M | - | - | - | - | |||||
Total Assets | 13.17B | 13.18B | 12.96B | 10.07B | - |
Select your edition
All financial news and data tailored to specific country editions
